Legal & General Group
CODX

Legal & General Group’s Co-Diagnostics CODX Stock Holding History

Legal & General Group’s Portfolio CODX Stock Details CODX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q2 		– Sell
-135
Closed -$39K – 3521
2021
Q1 		$39K Sell
135
-6
-4% -$2.4K ﹤0.01% 2901
2020
Q4 		$40K Hold
141
– – ﹤0.01% 2860
2020
Q3 		$57K Sell
141
-37
-21% -$19K ﹤0.01% 2647
2020
Q2 		$103K Buy
+178
New +$81.2K ﹤0.01% 2518

Other funds holding CODX

Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
PPA
Parametric Portfolio Associates Seattle, Washington $190B AUM 18.52% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
ARC
Advisor Resource Council Dallas, Texas $355M AUM 30.05% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $93.1B AUM 28.26% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
Susquehanna International Group
Susquehanna International Group Bala Cynwyd, Pennsylvania $893B AUM 36.07% 1-Year Est. Return
Bank of New York Mellon
Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Legal & General Group's CODX Position: Q2 2021 in Review

Legal & General Group sold out of Co-Diagnostics (CODX) in Q2 2021, closing a stake of 135 shares — an estimated $39K sold.

Legal & General Group first reported a position in CODX in Q2 2020 and held it in 4 quarters. The position peaked at $103K in Q2 2020. 88 funds tracked by Wall St. Rank hold CODX as of Q2 2021.

  • Legal & General Group reported no remaining Co-Diagnostics position as of Q2 2021 after selling out during the quarter.
  • Legal & General Group sold 135 Co-Diagnostics shares in Q2 2021, an estimated $39K.
  • Legal & General Group first reported a position in Co-Diagnostics in Q2 2020 and held it in 4 quarters.
  • Legal & General Group's Co-Diagnostics position peaked at $103K in Q2 2020.
  • 88 funds tracked by Wall St. Rank held Co-Diagnostics as of Q2 2021.

Based on Legal & General Group's 13F filing for Q2 2021, filed 12 Aug 2021.